Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

Drug-Drug Interaction Study in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: K-877
Drug: Rifampin

First Posted Date: 2014-10-27

Last Posted Date: 2016-02-01

Lead Sponsor: Kowa Research Institute, Inc.

Target Recruit Count: 20

Registration Number: NCT02275962

Locations: 🇺🇸
PPD, Austin, Texas, United States

Assessing PA-824 for Tuberculosis (the APT Trial)

Phase 2

Completed

Conditions: Pulmonary Tuberculosis

Interventions: Drug: PA-824
Drug: Rifampin
Drug: Rifabutin
Drug: Pyrazinamide
Drug: Ethambutol
Drug: Isoniazid

First Posted Date: 2014-10-06

Last Posted Date: 2023-07-18

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 157

Registration Number: NCT02256696

Locations: 🇿🇦
University of Cape Town Lung Institute, Cape Town, South Africa

A Study of LY2835219 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: LY2835219
Drug: Rifampin

First Posted Date: 2014-10-03

Last Posted Date: 2019-01-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT02256267

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States

COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients

Phase 1

Completed

Conditions: Medical Oncology

Interventions: Drug: Rifampin
Drug: Copanlisib (BAY80-6946)
Drug: Itraconazole

First Posted Date: 2014-10-01

Last Posted Date: 2020-12-14

Lead Sponsor: Bayer

Target Recruit Count: 51

Registration Number: NCT02253420

PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: TMC207
Drug: rifapentine
Drug: rifampicin

First Posted Date: 2014-08-13

Last Posted Date: 2019-09-06

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 32

Registration Number: NCT02216331

Locations: 🇺🇸
Celerion (MDS Pharma Services), Lincoln, Nebraska, United States

Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Procedure: Pharmacokinetic sampling - AZD9291
Drug: Rifampicin
Drug: AZD9291 tablet dosing
Procedure: Pharmacokinetic sampling - rifampicin
Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550

First Posted Date: 2014-07-22

Last Posted Date: 2021-07-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 41

Registration Number: NCT02197247

Locations: 🇬🇧
Research Site, Manchester, United Kingdom

Study to Evaluate the Effect of Multiple Doses of Rifampicin on the Multiple-dose Pharmacokinetics of Linagliptin in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rifampicin
Drug: Linagliptin

First Posted Date: 2014-07-08

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02183584

Relative Bioavailability of Single Doses of Dabigatran Etexilate in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran etexilate
Drug: Rifampicin

First Posted Date: 2014-06-25

Last Posted Date: 2014-06-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02173717

High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study

Phase 2

Completed

Conditions: Tuberculosis, Meningeal

Interventions: Drug: Placebo
Drug: Rifampicin
Drug: Other TB drugs
Drug: Adjuvant dexamethasone

First Posted Date: 2014-06-23

Last Posted Date: 2017-06-01

Lead Sponsor: Universitas Padjadjaran

Target Recruit Count: 60

Registration Number: NCT02169882

Locations: 🇮🇩
Hasan Sadikin General Hospital, Bandung, Jawa Barat, Indonesia

A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men

Phase 1

Completed

Conditions: Healthy Subjects
Drug-Drug Interaction (DDI)
Pharmacokinetics of Enzalutamide

Interventions: Drug: enzalutamide
Drug: rifampin

First Posted Date: 2014-05-15

Last Posted Date: 2014-10-15

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 28

Registration Number: NCT02138799

Locations: 🇩🇪
Parexel International GmbH, Berlin, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy